Alan S. Coates

University of Sydney — Australia

Biochemistry, Genetics and Molecular Biology · Life Sciences

98h-index52.9kcitations418works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(197), Estrogen and related hormone effects(112), Cancer Treatment and Pharmacology(60), HER2/EGFR in Cancer Research(56), Advanced Breast Cancer Therapies(56)

Publications415 total

Prognostic value of patient‐reported depression in women with hormone‐responsive early breast cancer in TEXT and SOFT
Cancer·2025
The WinPro trial: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer.
Journal of Clinical Oncology·2025
Associations between gut microbiota and weight loss in an energy-restricted dietary intervention trial in adults with elevated adiposity
Proceedings of The Nutrition Society·2025Open Access
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials
JCO Precision Oncology·2025· 1 citedOpen Access
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
Annals of Oncology·2023· 41 citedOpen Access
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Journal of Clinical Oncology·2022· 142 citedOpen Access
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Journal of Clinical Oncology·2022· 54 citedOpen Access
Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials
Cancer Research·2022· 8 cited
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy
Annals of Oncology·2021· 30 citedOpen Access
Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial
Cancer·2020· 7 citedOpen Access
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial
Breast Cancer Research and Treatment·2020· 13 cited
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
Breast Cancer Research and Treatment·2020· 37 citedOpen Access
The legacy of Professor Aron Goldhirsch
Annals of Oncology·2020
Abstract P5-12-01: SOLE (study of letrozole extension), a phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC): Final analysis and sole estrogen substudy (SOLE-EST)
Cancer Research·2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
British Journal of Cancer·2020· 5 citedOpen Access
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence
Breast Cancer Research·2019· 17 citedOpen Access
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
Journal of Clinical Oncology·2019· 143 citedOpen Access
The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer
Oncology Abstracts·2019
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.
Journal of Clinical Oncology·2019
Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311
Breast Cancer Research and Treatment·2019· 3 cited
page 1 of 21Next →

Frequent Co-authors

Richard D. Gelber(39), Aron Goldhirsch(35), Beat Thürlimann(23), Karen N. Price(22), Monica Castiglione‐Gertsch(17), Marco Colleoni(15), Giuseppe Viale(14), Meredith M. Regan(12), John Forbes(11), Diana Crivellari(8), Eric P. Winer(7), Manuela Rabaglio(7), Jurij Lindtner(7), Hans-Jörg Senn(6), Martine Piccart(6), Hervé Bonnefoi(6), Angelo Di Leo(6), James N. Ingle(6), Rudolf Maibach(6), Anita Giobbie‐Hurder(6)